# US 2010/0137305 A1 · Aminopyrimidines useful as kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137305 A1
- Document ID: US20100137305A1
- Status: Published application
- Kind: A1
- Application number: 12/562,181
- Filed: 2009-09-18
- Published: 2010-06-03
- Earliest claimed: 2008-09-18
- Assignees: Vertex Pharmaceuticals Incorporated
- Inventors: Hayley Binch; Stephen Young; Christopher Davis; Michael Mortimore; John Studley; Daniel Robinson; Michael O'Donnell; Dean Boyall; Joanne Pinder; Simon Everitt; Julian Golec
- Web page: https://patentgrep.com/patent/US20100137305A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Ht is
R2 is H, C1-3 alkyl, or cyclopropyl;
R2′ is H;
Q is —O—, —S—, or —C(R′)2—;
RX is H or F;
RY is
J1 is F, NR4R5, CN, OR6, oxo (═O), or C2-6alkyl optionally substituted with 1 occurrence of OH or OCH3;
each J2 is independently C1-6alkyl, F, NR4R5, CN, or OR6; or two J2 groups, together with the atom(s) to which they are bound, form a 4-7 membered heterocyclyl ring containing 1-2 heteroatoms selected from N or O; wherein said ring is optionally substituted with 0-3 JR;
n is 1 or 2;
R4 is H, C1-5alkyl, or C3-6 cycloalkyl;
R5 is C1-5alkyl or C3-6 cycloalkyl;
or R4 and R5, together with the nitrogen atom to which they are bound, form a 3-6 membered monocyclic ring containing 1-2 heteroatoms selected from O, N, or S; wherein said monocyclic ring is optionally substituted with 0-3 JR;
R6 is H, C1-4alkyl or C3-6 cycloalkyl; wherein said C1-4alkyl or C3-6 cycloalkyl is optionally substituted with 1-3 fluorine atoms;
JR is F or R7;
R1 is phenyl or a 6-membered heteroaryl ring, wherein said heteroaryl has 1-4 ring heteroatoms selected from O, N, and S; R1 is optionally substituted with 0-4 occurrences of —NHC(O)R3 or 0-4 fluorine atoms;
R3 is C1-6aliphatic or phenyl, wherein said R3 is optionally substituted with 0-6 J3;
each J3 is independently halo, C1-6alkyl, —O—(C1-6alkyl), —S—(C1-6 alkyl), nitro, or CN, wherein said C1-6alkyl group is optionally substituted with 0-3 flourine atoms; or two J3 groups, together with the carbon atom to which they are bound, form a 3-5 membered monocyclic group containing 0-1 heteroatom selected from O, N, and S;
each R7 is independently C1-6 aliphatic; a 5-6 membered heteroaryl containing 1-4 heteroatoms selected from O, N, or S; each R7 is optionally substituted with 0-3 J7; and
J7 is independently NH2, NH(C1-4aliphatic), N(C1-4aliphatic)2, halogen, C1-4aliphatic, OH, O(C1-4aliphatic), NO2, CN, CO2H, CO2(C1-4aliphatic), O(haloC1-4aliphatic), or haloC1-4aliphatic.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Q is S.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or claim 2, wherein RX is H.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein R2 is C1-3alkyl or cyclopropyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R2 is C1-3 alkyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any one of claims 1-5, wherein R2′ is H.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein R1 is phenyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein Ht is

### Claim 9 (depends on 7)

The compound of claim 7, wherein Ht is

### Claim 10 (depends on 8, 9)

The compound of claim 8 or claim 9, wherein n is 1.

### Claim 11 (depends on 8, 9)

The compound of claim 8 or claim 9, wherein n is 2.

### Claim 12 (depends on 10, 11)

The compound of claim 10 or claim 11, wherein each J2 is independently C1-6alkyl, F, NR4R5, CN, or OR6.

### Claim 13 (depends on 10, 11)

The compound of claim 10 or claim 11, wherein two J2 groups, together with the atom(s) to which they are bound, form a 4-7 membered heterocyclyl ring containing 1-2 heteroatoms selected from N or O; wherein said ring is optionally substituted with 0-3 JR.

### Claim 14 (depends on 12, 13)

The compound of claim 12 or claim 13, wherein R1 is substituted at the para position.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R1 is optionally substituted with 1 occurrence of —NHC(O)R3.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R3 is C1-6aliphatic wherein said R3 is optionally substituted with 0-6 J3.

### Claim 17 (depends on 16)

The compound of claim 16, wherein R3 is —CH2CH3, —CH2CF3, —CH2CH2CF3, cyclopropyl, or

### Claim 18 (depends on 15)

The compound of claim 15, wherein R3 is phenyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R3 is substituted in the ortho position with J3.

### Claim 20 (depends on 19)

The compound of claim 19, wherein J3 is halogen, —CF3, C1-3alkyl, —S—(C1-3alkyl), or OCF3.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 14, 15, 16, 17, 18, 19, 20)

The compound of any one of claims 1-9, 14-20, wherein
RY is
n is 2; and
two J2 groups, together with the atom(s) to which they are bound, form a 4-7 membered heterocyclyl ring containing 1-2 heteroatoms selected from N or O; wherein said ring is optionally substituted with 0-3 JR.

### Claim 22 (depends on 21)

The compound of claim 21, wherein the two J2 groups, together with the atom to which they are bound, form a 4-7 membered spirocyclic heterocyclyl ring containing 1-2 heteroatoms selected from N or O; wherein said ring is optionally substituted with 0-3 JR.

### Claim 23 (depends on 21)

The compound of claim 21, wherein the two J2 groups together with the atom(s) to which they are bound, form a 5-membered spirocyclic heterocyclyl ring containing 1 heteroatom selected from N or O; wherein said ring is optionally substituted with 0-3 JR.

### Claim 24 (depends on 23)

The compound of claim 23, wherein the two J2 groups together with the atom(s) to which they are bound, form a 5-membered spirocyclic heterocyclyl ring containing 1 N heteratom; wherein said ring is optionally substituted with 0-3 JR.

### Claim 25 (depends on 24)

The compound of claim 24, wherein the two J2 groups together with the atom(s) to which they are bound, form a 5-membered spirocyclic heterocyclyl ring containing 1 N heteratom; wherein said ring is optionally substituted with 1 JR.

### Claim 26 (depends on 25)

The compound of claim 25, wherein the JR is R7 and the R7 is C1-6alkyl.

### Claim 27 (depends on 26)

The compound of claim 26, wherein R1 is phenyl and R1 is substituted with 0-4 occurrences of —NHC(O)R3.

### Claim 28 (depends on 27)

The compound of claim 27, wherein R3 is C1-6alkyl.

### Claim 29 (depends on 27)

The compound of claim 27, wherein R3 is cyclopropyl.

### Claim 30 (depends on 25)

The compound of claim 25, wherein R1 is

### Claim 31 (depends on 30)

The compound of claim 30, wherein RY is

### Claim 32 (depends on 31)

The compound of claim 31, wherein JR is CH3.

### Claim 33 (depends on 30, 31, 32)

The compound of any one of claims 30-32, wherein R1 is

### Claim 34 (depends on 33)

The compound of claim 33, wherein R3 is C1-6aliphatic.

### Claim 35 (depends on 34)

The compound of claim 34, wherein R3 is ethyl or cyclopropyl.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein
RY is
n is 1;
J1 is F;
R1 is substituted with 1 occurrence of —NHC(O)R3;
R3 is C1-6aliphatic, wherein said R3 is substituted with 0-6 J3;
each J3 is halo.

### Claim 37 (depends on 36)

The compound according to claim 36, wherein RY is

### Claim 38 (depends on 37)

The compound according to claim 37, wherein RY is

### Claim 39 (depends on 36, 37, 38)

The compound according to any one of claims 36-38, wherein R3 is CH2CF3 or CH2CH2CF3.

### Claim 40 (depends on 36, 37, 38)

The compound according to any one of claims 36-38, wherein R3 is ethyl or cyclopropyl.

### Claim 41 (depends on 39)

The compound according to claim 39, wherein R3 is CH2CF3.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein
R1 is
n is 1;
J1 is NR4R5;
R1 is substituted with 1 occurrence of —NHC(O)R3;
R3 is C1-6aliphatic, wherein said R3 is substituted with 0-6 J3;
each J3 is halo.

### Claim 43 (depends on 41)

The compound according to claim 41, wherein RY is

### Claim 44 (depends on 42)

The compound according to claim 42, wherein RY is

### Claim 45 (depends on 42, 43, 44)

The compound according to any one of claims 42-44, wherein R3 is CH2CF3 or CH2CH2CF3.

### Claim 46 (depends on 42, 43, 44)

The compound according to any one of claims 42-44, wherein R3 is ethyl or cyclopropyl.

### Claim 47 (depends on 45)

The compound according to claim 45, wherein R3 is CH2CF3.

### Claim 48 (depends on 1)

The compound of claim 1 wherein the compounds are selected from the following:

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A composition comprising a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein the variables are as defined according to any one of claims 1-48.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method of inhibiting Aurora protein kinase activity in a biological sample comprising contacting said biological sample with a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein the variables are as defined according to any one of claims 1-48.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method of treating a proliferative disorder in a patient comprising the step of administering to said patient a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein the variables are as defined according to any one of claims 1-48.

### Claim 52 (depends on 49)

The method according to claim 49, wherein said proliferative disorder is cancer.

### Claim 53 (depends on 49)

The method according to claim 49, wherein said proliferative disorder is selected from melanoma, myeloma, leukemia, lymphoma, neuroblastoma, or a cancer selected from colon, breast, gastric, ovarian, cervical, lung, central nervous system (CNS), renal, prostate, bladder, pancreatic, brain (gliomas), head and neck, kidney, liver, melanoma, sarcoma, or thyroid cancer.

### Claim 54 (depends on 51, 52, 53)

The method according to claim 51-53 further comprising the sequential or co-administration of a therapeutic agent.

### Claim 55 (depends on 54)

The method according to claim 54, wherein said therapeutic agent is selected from taxanes, inhibitors of bcr-abl, inhibitors of EGFR, DNA damaging agents, and antimetabolites.

### Claim 56 (depends on 54)

The method according to claim 54, wherein said therapeutic agent is selected from Paclitaxel, Gleevec, dasatinib, nilotinib, Tarceva, Iressa, cisplatin, oxaliplatin, carboplatin, anthracyclines, AraC and 5-FU.

### Claim 57 (depends on 54)

The method according to claim 54, wherein said therapeutic agent is selected from camptothecin, doxorubicin, idarubicin, Cisplatin, taxol, taxotere, vincristine, tarceva, the MEK inhibitor, U0126, a KSP inhibitor, vorinostat, Gleevec, dasatinib, and nilotinib.

### Claim 58 (depends on 54)

The method according to claim 54, wherein said therapeutic agent is dasatinib.

### Claim 59 (depends on 54)

The method according to claim 54, wherein said therapeutic agent is nilotinib.
